HemaSphere (May 2023)

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

  • M. Gertz,
  • A. Cohen,
  • R. Comenzo,
  • E. Kastritis,
  • H. Landau,
  • E. Libby,
  • M. Liedtke,
  • V. Sanchorawala,
  • S. Schönland,
  • A. Wechalekar,
  • Y. Ando,
  • Y. Koh,
  • J. Zonder,
  • G. Palladini,
  • C. Nie,
  • C. Karp,
  • Y. Jin,
  • A. Conrad,
  • G. Kinney,
  • G. Merlini

DOI
https://doi.org/10.1097/01.HS9.0000936352.84768.4d
Journal volume & issue
Vol. 7, no. S2
pp. 41 – 42

Abstract

Read online

No abstracts available.